Biopharmaceutical companies across the globe have been working hard to develop a vaccine against COVID-19. A New York Regeneron lab, which utilizes equipment supplied by several Flow Control Group companies — including Purity One™ and PharmOvate-Triangle Process Equipment — is aggressively working to develop and produce new therapeutic antibodies for the virus.
NBC Nightly News’ Lester Holt recently interviewed Regeneron’s co-founders Leonard S. Schleifer, M.D., Ph.D., and George D. Yancopoulos, M.D., Ph.D., and Regeneron’s Vice President of Research Christos Kyratsous, Ph.D., about the company’s incredible efforts to develop a treatment. Dr. Leonard Schleifer is confident in the company’s ability to develop a vaccine.
“We are optimistic because we’ve done this approach to treat many human diseases,” he said.
The company’s drug candidate will be studied as both a way to prevent infection and to treat people with the virus. Regeneron moved its most potent antibodies into pre-clinical and clinical-scale cell production lines in mid-April.
An ability to quickly scale a COVID-19 treatment will be essential. According to Regeneron’s website, the company is on track to have enough product ready to begin human testing in June, and plans to scale production “to have hundreds of thousands of preventative doses or tens of thousands of treatment doses per month by the end of August.”
A stable supply chain is essential to success during these challenging times. To learn about the Purity One™ fluid transfer solutions that are contributing to this undertaking, please contact a rep today.
Biopharmaceutical companies across the globe have been working hard to develop a vaccine against COVID-19. A New York Regeneron lab, which utilizes equipment supplied by several Flow Control Group companies — including Purity One™ and PharmOvate-Triangle Process Equipment — is aggressively working to develop and produce new therapeutic antibodies for the virus.
NBC Nightly News’ Lester Holt recently interviewed Regeneron’s co-founders Leonard S. Schleifer, M.D., Ph.D., and George D. Yancopoulos, M.D., Ph.D., and Regeneron’s Vice President of Research Christos Kyratsous, Ph.D., about the company’s incredible efforts to develop a treatment. Dr. Leonard Schleifer is confident in the company’s ability to develop a vaccine.
“We are optimistic because we’ve done this approach to treat many human diseases,” he said.
The company’s drug candidate will be studied as both a way to prevent infection and to treat people with the virus. Regeneron moved its most potent antibodies into pre-clinical and clinical-scale cell production lines in mid-April.
An ability to quickly scale a COVID-19 treatment will be essential. According to Regeneron’s website, the company is on track to have enough product ready to begin human testing in June, and plans to scale production “to have hundreds of thousands of preventative doses or tens of thousands of treatment doses per month by the end of August.”
A stable supply chain is essential to success during these challenging times. To learn about the Purity One™ fluid transfer solutions that are contributing to this undertaking, please contact a rep today.
Recent Posts